Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05902702

Isotonic Saline for Children With Bronchiolitis

The goal of this randomized clinical trial is to investigate the optimal supportive treatment of bronchiolitis in infants from 0-12 months of age. The main question[s] it aims to answer are:

* To investigate whether isotonic saline should be used as supportive treatment for children with bronchiolitis, and if so, identify the optimal route of administration. The primary outcome is duration of hospitalization. * To investigate the current epidemiology of the viral pathogens causing bronchitis in children in Denmark, and to assess whether children infected with specific pathogens might benefit from treatment with isotonic saline.

The children are randomized after inclusion through computer randomization to one of the 3 arms in the study:

1. Nebulized isotonic saline 2. Nasal irrigation with isotonic saline 3. No treatment with saline

The investigators will compare treatment with saline (both methods) with no treatment, and the investigators will also compare the two methods of delivery of saline (nebulized vs. nasal irrigation).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Design: An investigator-initiated, multicenter, open label, three-arm randomized, controlled non-inferiority trial.

Study sites: Seven pediatric departments in eastern Denmark (Slagelse Hospital, Holbæk Hospital, Zealand University Hospital Roskilde, Copenhagen University Hospital Hvidovre, Copenhagen University Hospital Herlev, Nordsjaellands Hospital, and Nykoebing Falster Hospital).

Participants: Children aged 0-12 months admitted to a pediatric department or emergency department in eastern Denmark with bronchiolitis, whose parents provide informed consent for participation.

Randomization: Participating children are randomized 1:1:1 through computer randomization to either nebulized isotonic saline, nasal irrigation with isotonic saline or no isotonic saline therapy at all. Participating children will have a nasal sample collected and tested for a panel of viral pathogens. Excess material (1 ml nasal lining fluid) from upper airway respiratory samples will be stored in a research biobank until 31.12.2030 and used for sub-phenotyping of bronchiolitis and for developing personalized treatment and prediction of later asthma by means of host transcriptomics and metabolomics, 16S sequencing of the airway microbiome and meta-transcriptomics.

All other treatment is given according to standard of care guidelines.

Sample size: By including 249 children in total (83 in each arm) the investigators can prove non-inferiority of nasal irrigation or nebulized saline relative to no saline with a non-inferiority limit of 12 hours admission, alpha 2.5% and a power of 80%. The investigators aim to include 300 children in total to account for dropouts.

Recruitment: Children will only be included if both parents provide informed consent.

Perspectives: This study may improve current practice for supportive treatment of children with bronchiolitis. If saline is found to be helpful, it may be implemented into global guidelines. If no effect of saline is found, physicians may stop spending resources and manpower on an ineffective and potentially unpleasant treatment. Second, if saline is effective, but nasal irrigation proves to be non-inferior to nebulization, it may also reduce the workload of nurses, and possibly duration of hospitalization, because the treatment can be delivered by the parents at home. Moreover, the parents are empowered to manage their child's illness themselves, potentially improving the experience of parents as well as the affected child.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children aged 0-12 months, whose parents give informed consent to participate, with symptoms of bronchiolitis including at least one of:
  • Runny nose
  • Dry and persistent cough
  • Labored breathing (tachypnea, retractions, nasal flaring)
  • Grunting
  • Cyanosis or apnea
  • Wheezing or crackles on auscultation
  • O2 saturations below 92 %
  • Difficulties feeding

Exclusion criteria

  • Children with cystic fibrosis or other serious congenital lung diseases
  • Children in whom treatment with short-acting beta-2 agonist is initiated (as this is delivered in nebulized isotonic saline).

Treatment and study plan

Nebulized isotonic saline

Other

The intervention will constitute nebulized isotonic saline.

Nasal irrigation with isotonic saline

Other

The intervention will constitute isotonic saline administered as nasal drops.

Primary outcomes

  1. Duration of hospitalization

    Time frame: 0-7 days typically (max 14 days)

    In hours

Secondary outcomes

  1. Number of participants needing respiratory support

    Time frame: During admission (up to day 14)

    The need for respiratory support with nasal continuous positive airway pressure or high-flow oxygen therapy.

  2. Number of participants being readmitted after discharge

    Time frame: 30 days after discharge

    If readmitted to the hospital

  3. Respiratory severity score

    Time frame: During admission (up to day 14)

    Respiratory Severity Score with Heart Rate (RSS-HR), scale from 0-12, higher score means worse outcome.

  4. Number of participants needing oxygen therapy

    Time frame: During admission (up to day 14)

    Need for oxygen therapy

  5. Number of participants needing transfer to ICU or SICU

    Time frame: During admission (up to day 14)

    Transfer to the intensive care unit or semi-intensive care unit

  6. Health-related Quality of Life

    Time frame: Up to one month after discharge

    Health-related Quality of Life questionnaire developed by Díez-Gandía et al. (PMID: 34488668) including 12 items. Item responses will be scored using the following algorithm (unweighted method): (1) Each response item will be assigned a value according to its gravity (1 = best level or 9 = worst level). (2) The sum of the scores will be standardized using the min-max normalization to a 0-1-point scale, with 1 indicating the best quality of life and 0 the worst.

  7. Fluid supplements

    Time frame: During admission (up to day 14)

    Requirement of fluid supplements either by nasogastric tube or intravenous

  8. pCO2

    Time frame: During admission (up to day 14)

    Highest pCO2 measured

  9. Number of participants needing to switch treatment

    Time frame: During admission (up to day 14)

    Clinician-initiated switch to the opposite treatment from the one they were randomized to

  10. Number of participants with visible distress

    Time frame: During admission (up to day 14)

    Visible distress in the child during delivery of treatment

  11. Parents satisfaction

    Time frame: Up to one month after discharge

    Parents satisfaction with the given treatment, questionnaire developed by the investigators exploring satisfaction of 3 items on a scale from 1-10 (total score from 3-30) where higher score means better outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Ann-Marie M Schoos, MD, PhD

CONTACT

[email protected]

+45 20681250

Maren J Rytter, MD, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Slagelse Hospital

Other

Collaborators

  • Copenhagen University Hospital at Herlev
  • Copenhagen University Hospital, Hvidovre
  • Holbaek Sygehus
  • Nordsjaellands Hospital
  • Nykøbing Falster Hospital
  • Zealand University Hospital

Registry information

Official study title

Isotonic Saline for Children With Bronchiolitis - a Randomized Controlled Non-inferiority Trial

Important dates

Study start
2023
Primary completion
2024
Study completion
2029
First posted
Jun 15, 2023
Registry last updated
Jun 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.